Nutropin AQ/Increlex injection: Preliminary Phase II data

Preliminary data from the ongoing, open-label, U.S. Phase II MS316 trial in 36 evaluable patients showed that once-daily Increlex (50, 100 or 150 µg/kg) plus 45 µg/kg Nutropin AQ led to respective first-year height velocities of 10.4, 10.7 and 12.1 cm vs. 9.2 cm for once-daily 45 µg/kg Nutropin AQ alone. At 1 year, changes in mean SD score were 0.88, 0.91 and 1.11 for the 3 combination regimens vs. 0.72 for Nutropin AQ alone. Data were presented at the joint meeting of the Lawson Wilkins Pediatric Endocrine Society and the European Society for Pediatric Endocrinology in New York. ...